Submission of Investor Complaints for the quarter and year ended 31st March, 2026
Awaiting price reaction for this filing.
MPS Pharmaa Limited (formerly Advik Laboratories Limited) has submitted its quarterly investor complaints report for Q4 FY2026 ending 31st March 2026, as required under SEBI (LODR) Regulation 13(3). The filing shows zero investor complaints across all categories during the quarter. No complaints were pending at the beginning of the quarter, none were received, none were disposed of, and none remained unresolved at the end of the quarter. The company also noted its name change from Advik Laboratories Limited to MPS Pharmaa Limited. This is a routine regulatory compliance filing with BSE and ASE.
Zero investor complaints during the quarter indicates smooth shareholder grievance management and good corporate governance. The name change from Advik Laboratories to MPS Pharmaa Limited may require investors to update their records for trading and holdings.